The purpose of the imaging core is to support Projects 1, 2 and 3 for the experimental research studies proposed in this Parkinson's disease 9PD) Research Center program. Specific activities of the core are: 1) To provide all MRI, MRS and PET studies for pre- and post-operative experiments of all parkinsonian MPTP monkeys. 2) To provide in vivo monitoring for the progressive development of PD in primates and the neuroprotection provided by the interventions listed in Project 1. The dopamine synapse loss index curves derived by PET from the current animal models (see preliminary data) will allow an investigation of such neuroprotective or restorative interventions, mainly through the use of radioactively labeled CFT (dopamine reuptake sites) and MRS studies of neurochemicals. 3) To provide physiological information of cerebral hemodynamics, glucose metabolism and dopaminergic function that different transplantation protocols into striatum, substantia nigra and subthalamic nucleus using and human fetal cells (Project 2.) And stem cells (PROJECT 3.) to examine motor circuitry based on dopaminergic reinnervation. 4) To enable research fellows to train in neural imaging techniques and technology for PD. The combined PET and MRI core facility provides an educational environment for fellows in which a large database can be compared to the experimental animals planned. The usefulness and application of these methods also allow a comparative data set to the MGH/McLean and HARVARD Primate Center facilities. Novel experiments and training opportunities are therefore abundant.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mc Lean Hospital (Belmont, MA)
United States
Zip Code
Wang, Xin; Li, Nuomin; Xiong, Nian et al. (2017) Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson's Disease. Mol Neurobiol 54:2878-2888
Xiong, Nian; Li, Nuomin; Martin, Eden et al. (2016) hVMAT2: A Target of Individualized Medication for Parkinson's Disease. Neurotherapeutics 13:623-34
Hallett, Penelope J; Deleidi, Michela; Astradsson, Arnar et al. (2015) Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell 16:269-74
Hallett, Penelope J; Cooper, Oliver; Sadi, Damaso et al. (2014) Long-term health of dopaminergic neuron transplants in Parkinson's disease patients. Cell Rep 7:1755-61
Lindvall, Olle; Barker, Roger A; Brüstle, Oliver et al. (2012) Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell 10:151-5
Cooper, Oliver; Hallett, Penny; Isacson, Ole (2012) Using stem cells and iPS cells to discover new treatments for Parkinson's disease. Parkinsonism Relat Disord 18 Suppl 1:S14-6
Hallett, Penelope J; McLean, Jesse R; Kartunen, Andrew et al. (2012) ýý-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis 47:258-67
McLean, Jesse R; Hallett, Penelope J; Cooper, Oliver et al. (2012) Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol Cell Neurosci 49:230-9
Deleidi, Michela; Isacson, Ole (2012) Viral and inflammatory triggers of neurodegenerative diseases. Sci Transl Med 4:121ps3
Deleidi, Michela; Cooper, Oliver; Hargus, Gunnar et al. (2011) Oct4-induced reprogramming is required for adult brain neural stem cell differentiation into midbrain dopaminergic neurons. PLoS One 6:e19926

Showing the most recent 10 out of 91 publications